Advanced in Adult Soft Tissue Sarcoma

Dr. Mark E. Borowsky

Oncology
HackenSack Meridian health
HMH - Obstetrics And Gynecology - Neptune
19 Davis Avenue, Floor 7, 
Neptune, NJ 
Advanced in Adult Soft Tissue Sarcoma
HackenSack Meridian health
HMH - Obstetrics And Gynecology - Neptune
19 Davis Avenue, Floor 7, 
Neptune, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Borowsky is an Oncologist in Neptune, New Jersey. Dr. Borowsky is rated as an Advanced provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Ureteral Reconstruction, and Hernia Surgery.

His clinical research consists of co-authoring 17 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Adult Soft Tissue Sarcoma.

Graduate Institution
Perelman School Of Medicine At The University Of Pennsylvania
Residency
North Shore University Hospital-Manhasset
Specialties
Oncology
Licenses
Obstetrics & Gynecology in DE
Board Certifications
American Board Of Obstetrics And Gynecology
American Board Of Obstetrics And Gynecology
Fellowships
SUNY Downstate Medical Center
Hospital Affiliations
Ocean Medical Center
Riverview Medical Center
Jfk University Medical Center
Jersey Shore University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

HMH - Obstetrics and Gynecology - Neptune
19 Davis Avenue, Floor 7, Neptune, NJ 7753.
Call: 732-897-7944
Other Locations
1 Hospital Plaza, Suite 206, Old Bridge, NJ 8857.
Call: 732-530-2410
HMH - Obstetrics and Gynecology - Forked River
730 Lacey Road, Suite 206, Forked River, NJ 8731.
Call: 732-897-7944
HMH - Gynecologic Oncology - Jackson
27 South Cooks Bridge Road, Suite 2-19, Jackson, NJ 8527.
Call: 732-530-2410

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva
A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva
Enrollment Status: Completed
Publish Date: August 25, 2023
Intervention Type: Biological, Drug, Device
Study Drugs: VGX-3100, Imiquimod Cream
Study Phase: Phase 2
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
Enrollment Status: Unknown
Publish Date: December 29, 2021
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
View 6 Less Clinical Trials

17 Total Publications

Extended Venous Thromboembolism Prophylaxis after Robotic Staging for Endometrial Cancer.
Extended Venous Thromboembolism Prophylaxis after Robotic Staging for Endometrial Cancer.
Journal: Southern medical journal
Published: October 03, 2023
View All 17 Publications
Similar Doctors
Elite in Adult Soft Tissue Sarcoma
Dr. Sandra Dangelo
Oncology
Elite in Adult Soft Tissue Sarcoma
Dr. Sandra Dangelo
Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (38.7 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sandra Dangelo is an Oncologist in New York, New York. Dr. Dangelo is rated as an Elite provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Liposarcoma, Merkel Cell Carcinoma, and Liver Embolization.

Elite in Adult Soft Tissue Sarcoma
Dr. Mrinal M. Gounder
Oncology
Elite in Adult Soft Tissue Sarcoma
Dr. Mrinal M. Gounder
Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (38.7 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mrinal Gounder is an Oncologist in New York, New York. Dr. Gounder is rated as an Elite provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Desmoid Tumor, Epithelioid Sarcoma, Liposarcoma, and Liver Embolization.

Elite in Adult Soft Tissue Sarcoma
Dr. Sujana Movva
Oncology | Hematology Oncology | Hematology
Elite in Adult Soft Tissue Sarcoma
Dr. Sujana Movva
Oncology | Hematology Oncology | Hematology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (38.7 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sujana Movva is an Oncologist and a Hematologist Oncology provider in New York, New York. Dr. Movva is rated as an Elite provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Gastrointestinal Stromal Tumor, Pancreaticoduodenectomy, and Splenectomy.

VIEW MORE ADULT SOFT TISSUE SARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Borowsky's expertise for a condition
ConditionClose
    • Distinguished
    • Cervical Cancer
      Dr. Borowsky is
      Distinguished
      . Learn about Cervical Cancer.
      See more Cervical Cancer experts
    • Endometrial Cancer
      Dr. Borowsky is
      Distinguished
      . Learn about Endometrial Cancer.
      See more Endometrial Cancer experts
    • Endometrial Stromal Sarcoma
      Dr. Borowsky is
      Distinguished
      . Learn about Endometrial Stromal Sarcoma.
      See more Endometrial Stromal Sarcoma experts
    • Lump in the Abdomen
      Dr. Borowsky is
      Distinguished
      . Learn about Lump in the Abdomen.
      See more Lump in the Abdomen experts
    • Malignant Mixed Mullerian Tumor
      Dr. Borowsky is
      Distinguished
      . Learn about Malignant Mixed Mullerian Tumor.
      See more Malignant Mixed Mullerian Tumor experts
    • Neuroendocrine Carcinoma of the Cervix
      Dr. Borowsky is
      Distinguished
      . Learn about Neuroendocrine Carcinoma of the Cervix.
      See more Neuroendocrine Carcinoma of the Cervix experts
    View All 7 Distinguished Conditions
    • Advanced
    • Adult Soft Tissue Sarcoma
      Dr. Borowsky is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Cervical Dysplasia
      Dr. Borowsky is
      Advanced
      . Learn about Cervical Dysplasia.
      See more Cervical Dysplasia experts
    • Endometritis
      Dr. Borowsky is
      Advanced
      . Learn about Endometritis.
      See more Endometritis experts
    • Neonatal Ovarian Cyst
      Dr. Borowsky is
      Advanced
      . Learn about Neonatal Ovarian Cyst.
      See more Neonatal Ovarian Cyst experts
    • Ovarian Carcinosarcoma
      Dr. Borowsky is
      Advanced
      . Learn about Ovarian Carcinosarcoma.
      See more Ovarian Carcinosarcoma experts
    • Ovarian Cysts
      Dr. Borowsky is
      Advanced
      . Learn about Ovarian Cysts.
      See more Ovarian Cysts experts
    View All 11 Advanced Conditions
    • Experienced
    • Adenomyosis
      Dr. Borowsky is
      Experienced
      . Learn about Adenomyosis.
      See more Adenomyosis experts
    • Angiomyoma
      Dr. Borowsky is
      Experienced
      . Learn about Angiomyoma.
      See more Angiomyoma experts
    • Bladder Reconstruction
      Dr. Borowsky is
      Experienced
      . Learn about Bladder Reconstruction.
      See more Bladder Reconstruction experts
    • Desmoplastic Small Round Cell Tumor
      Dr. Borowsky is
      Experienced
      . Learn about Desmoplastic Small Round Cell Tumor.
      See more Desmoplastic Small Round Cell Tumor experts
    • Endometrial Polyps
      Dr. Borowsky is
      Experienced
      . Learn about Endometrial Polyps.
      See more Endometrial Polyps experts
    • Endometriosis
      Dr. Borowsky is
      Experienced
      . Learn about Endometriosis.
      See more Endometriosis experts
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.